{"filing":{"accession_number":"0001213900-26-097048","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"ea0304400-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026097048/ea0304400-6k_canfite.htm"},"events":[{"id":31538,"run_id":28945,"accession_number":"0001213900-26-097048","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Can-Fite entered into an inducement offer letter on September 2, 2026, whereby an existing warrant holder agreed to exercise warrants for 1,591,738 ADSs at a reduced price of $2.50 per ADS (down from $5.00), generating approximately $4.0 million in gross proceeds. In exchange, the Company issued new warrants to purchase 3,183,476 ADSs at $2.50 per ADS, plus placement agent warrants for 111,422 ADSs. This is a classic dilutive warrant exercise and issuance transaction—the holder receives double the warrant shares in exchange for exercising existing warrants at a discount, and the Company raises capital through a private placement exempt under Section 4(a)(2) of the Securities Act. The transaction materially increases share dilution and is disclosed as a capital-raising event.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-03","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":34461,"accession_number":"0001213900-26-097048","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Can-Fite entered into an inducement offer letter on September 2, 2026, whereby an existing warrant holder agreed to exercise warrants for 1,591,738 ADSs at a reduced price of $2.50 per ADS (down from $5.00), generating approximately $4.0 million in gross proceeds. In exchange, the Company issued new warrants to purchase 3,183,476 ADSs at $2.50 per ADS, plus placement agent warrants for 111,422 ADSs. This is a classic dilutive warrant exercise and issuance transaction—the holder receives double the warrant shares in exchange for exercising existing warrants at a discount, and the Company raises capital through a private placement exempt under Section 4(a)(2) of the Securities Act. The transaction materially increases share dilution and is disclosed as a capital-raising event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-03T15:44:50.265536+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-03"}]}